The termination of the ATM program removes near-term overhang from continuous equity sales, but the $69.3M shelf registration remains a significant future dilution risk. Monitor for any new takedowns under the shelf or any operational catalysts that could change the capital needs.
Price Chart
Executive Summary
Artelo Biosciences terminated its At-The-Market (ATM) equity offering agreement with R.F. Lafferty, effective May 18, 2026. The ATM program had a maximum capacity of $6.5M, but only $451,527 in gross proceeds was raised from 50,858 shares. This termination removes a source of future dilution, but the company still carries $69.3M in unsold securities on its shelf registration, preserving significant future dilution capacity.
Key Facts
- ATM Sales Agreement with R.F. Lafferty terminated effective May 18, 2026.
- Only $451,527 in gross proceeds raised from 50,858 shares under the ATM program.
- ATM program had a maximum aggregate offering price of $6,500,000.
- Company still has $69.3M of unsold securities on its S-3 shelf registration.
- Stock price at filing was $1.84 per share.
Financial Impact
Termination of a $6.5M ATM program that raised only $451,527. No new capital raised; existing $69.3M shelf capacity remains.
Risk Factors
- Future dilution from the $69.3M shelf registration remains a material risk.
- Low market cap ($4M) makes any equity issuance highly dilutive.
- Company has no approved products and limited revenue, increasing reliance on equity financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001640334-26-000926 |
| Document: 0001640334-26-000926-index-headers.html | 0001640334-26-000926 |
| Document: 0001640334-26-000926-index.html | 0001640334-26-000926 |
| Document: 0001640334-26-000926.txt | 0001640334-26-000926 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 8-K | $3.11 | awaiting T+60 | — | $2.33 (+25.08%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.33 (−37.87%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.33 (−65.89%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.33 (+104.39%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.33 (+104.39%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.33 (+121.90%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.33 (−109.91%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.33 (−59.59%) |
May 18, 2026 22w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.33 (+71.32%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.33 (+59.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers